The New BIOSECURE Act: An Improved New Regulatory Regime with the Devil Still in the Details

On Thursday, December 18, the President signed the National Defense Authorization Act (NDAA) for Fiscal Year 2026. The NDAA contains several new national security regulatory controls, including a new Section 851 “Prohibition on contracting with certain biotechnology providers” (the Act). The prohibition in the Act is a revised version of a bill introduced almost two years ago intended to discourage the U.S. government and U.S. biotechnology companies more broadly from relying on certain…
By: Wilson Sonsini Goodrich & Rosati